Provention receives $20 million nonrefundable payment granting Sanofi exclusive right of first negotiation to in-license teplizumab globally for T1D
U.S. copromotion agreement leverages Sanofi’s in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive T1D screening
Sanofi to invest $35 million at a premium after a potential teplizumab FDA approval
Investor Conference call at 8:30am ET Today
RED BANK, N.J. , Oct. 6, 2022 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB) (the “Company”), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has entered into a co-promotion agreement with Sanofi U.S. for the launch of Provention’s lead investigational drug candidate teplizumab. The agreement enables Provention Bio to leverage Sanofi’s expertise, capabilities and commercial resources to support the potential launch of teplizumab currently under review by the U.S. Food and Drug Administration (“FDA”), for the delay of clinical type 1 diabetes in at-risk individuals, with a user fee goal date of November 17, 2022 for the Biologics License Application.
“This collaboration with Sanofi U.S. allows us to significantly expand our planned commercial footprint during launch to support increased screening and product awareness as we work to launch a new therapy that, if approved, will dramatically impact the lives of the patients and families we serve,” said Jason Hoitt, Chief Commercial Officer, Provention Bio. “In particular, Sanofi’s long-standing relationships with key U.S. healthcare professionals will complement our focus on pediatric endocrinologists and help us address a larger patient population with greater efficiency.”
Olivier Bogillot, Head of U.S. General Medicines, Sanofi, stated, “We are delighted by the prospect of supporting Provention Bio in bringing to the U.S. what could become the first-in-class therapy to change the course of type 1 diabetes. If approved, Sanofi U.S. will leverage its existing world-class capabilities in diabetes care to enhance efforts in both patient and healthcare provider access. We are prepared to tap into all of our internal expertise to support the successful launch of this innovative therapy.”
“The agreement brings significant resources to Provention and allows us to advance our mission of delivering therapies which intercept or delay debilitating and life-threatening autoimmune diseases,” said Ashleigh Palmer, Co-Founder and Chief Executive Officer, Provention Bio. “We look forward to working with our colleagues at Sanofi as we prepare to deliver, if approved, the first-ever disease-modifying therapy for T1D.”
Co-Promotion Agreement 
Under the terms of the agreement, Sanofi will commit commercial resources in the United States, including diabetes field specialists, account directors, field-based reimbursement and medical science liaisons to expand the number of key healthcare professionals reached in the United States. In exchange, Provention will reimburse field force-related expenses that Sanofi will incur in connection with commercializing teplizumab under the agreement.
Provention retains all rights to teplizumab and maintains responsibility for the commercialization strategy.
Right of First Negotiation to Global Commercial Rights
The Company also granted Sanofi, in consideration of a one-time payment of $20 million, an exclusive, one-time right of first negotiation (ROFN) to obtain exclusive global rights to commercialize teplizumab for Type 1 diabetes indications in humans, subject to certain retained rights of the Company to engage in discussions with third parties with respect to certain transactions. Sanofi may exercise the ROFN, until June 30, 2023, with an option to extend within 2023 under certain conditions.
Equity Investment
Simultaneous with their entry into the co-promotion agreement, the Company and Sanofi entered into a Securities Purchase Agreement (the “Purchase Agreement”). Pursuant to the Purchase Agreement, if teplizumab is approved by the FDA, Sanofi has agreed to purchase $35 million of the Company’s common stock at a premium over the daily volume-weighted average per share price for the five consecutive trading days prior to the closing date. The closing date will be at Provention’s discretion and would occur no later than February 16, 2023.
BofA Securities acted as financial advisor to the Company on this transaction.
For important information related to the terms of the Co-Promotion Agreement and Securities Purchase Agreement, see Provention Bio’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 6, 2022.
Conference Call and Webcast Information
Provention Bio will discuss this business update via conference call today at 8:30 am ET. To access the call, please dial 1-888-347-7861 (domestic) or 1-412-902-4247 (international) ten minutes prior to the start time and ask to be connected to the “Provention Bio Call.” An audio webcast will also be available on the “Events and Webcasts” page of the Investors section of the Company’s website, An archived webcast will be available on the Company’s website approximately two hours after the conference call.
About Teplizumab
Teplizumab is an anti-CD3 monoclonal antibody that is being developed for the delay of clinical T1D in at-risk individuals, as indicated by the presence of two or more T1D-related autoantibodies. There has been no disease-modifying innovation for this life-impacting and life-threatening autoimmune disease since the development of insulin a century ago. More than 800 patients have received teplizumab in multiple clinical studies involving more than 1,000 subjects. Provention is currently also evaluating teplizumab in patients with newly diagnosed insulin-dependent T1D (the Phase 3 PROTECT study).
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay of progression to Stage 3 clinical type 1 diabetes in at-risk individuals has been filed by the U.S. Food and Drug Administration (FDA). The Company’s pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit for more information and follow us on Twitter: @ProventionBio.
Internet Posting of Information
Provention Bio, Inc. uses its website,, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company’s website in the “News” section. Accordingly, investors should monitor this portion of the Company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.
Forward-Looking Statements
Certain statements in this press release are forward-looking, including but not limited to, statements relating to the Company’s ability to leverage Sanofi’s expertise, capabilities and commercial resources to support the potential launch of teplizumab, the potential that the collaboration with Sanofi to significantly expand the Company’s planned commercial footprint during launch, the potential exercise of the ROFN by Sanofi, the potential approval and commercialization of teplizumab and the potential closing of the common stock offering to Sanofi. These statements may be identified by the use of forward-looking words such as “may” and “potential,” among others. These forward-looking statements are based on the Company’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to FDA disagreeing with the Company’s interpretation of data and analysis and information in the BLA resubmission; delays in or failure to obtain FDA approvals for teplizumab or other Company product candidates and the potential for noncompliance with FDA regulations; any inability to successfully work with FDA to address its concerns and requests in a timely manner or at all during the review process for teplizumab, including any inability to provide the FDA with data, analysis or other information sufficient to support an approval of the BLA for teplizumab; any inability to satisfactorily address matters related to PK comparability, product quality, safety or any other FDA requirements during the BLA review process to obtain an approval of teplizumab; the potential impacts of COVID-19 on our business and financial results; changes in law, regulations, or interpretations and enforcement of regulatory guidance; uncertainties of patent protection and litigation; the Company’s dependence upon third parties; substantial competition; the Company’s need for additional financing and the risks listed under “Risk Factors” in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2022 and any subsequent filings with the Securities and Exchange Commission. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Provention does not undertake an obligation to update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. The information set forth herein speaks only as of the date hereof.
Investor Contacts:
Thierry Chauche, Chief Financial Officer
Brendan Strong
Argot Partners
Media Contact:
Kaelan Hollon, VP of Communications 
View original content to download multimedia:
SOURCE Provention Bio, Inc.
Related Quotes
Nio (NYSE: NIO) stock crashed Thursday morning, sinking 6.5% lower as of 11:25 a.m. ET. The Chinese electric vehicle (EV) manufacturer is upping up its battery swap game and even setting up a battery manufacturing business. Investors in Chinese stocks are already scurrying for cover after Chinese leader Xi Jinping secured a third term earlier this week, as they fear Xi's ideologies, particularly his crackdowns on the private sector and zero-COVID policy, to continue.
Yahoo Finance's Allie Garfinkle previews Apple and Amazon earnings as tech companies face headwinds.
PC shipments fell 15.5% in the third quarter, data from Counterpoint Research showed. The research firm expects a 13% drop for the full year, higher than Intel's estimate of a roughly 10% decline. Chipmakers have also come under pressure from concerns that the threat of a global recession could prompt clients from the more lucrative data center market to wind down spending.
Friday is your last chance to buy at the 9.62% rate. But there are other important issues to consider.
Yahoo Finance Live anchors discuss Align earnings and the company's stock performance since the pandemic.
Mark Zuckerberg's plan to dominate the metaverse is turning into a nightmare for everyone. And it's costing real money.
Medical Properties (MPW) delivered FFO and revenue surprises of 0% and 9.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
In this article, we will discuss the 10 Best Value Stocks To Buy According To Warren Buffett. You can skip our detailed analysis of Berkshire Hathaway’s strategy and Warren Buffett’s background and go directly to the 5 Best Value Stocks To Buy According To Warren Buffett. Born in 1930 in Omaha, Nebraska, Warren Buffett is […]
Here's what to expect today from Amazon's Q3 earnings.
QuantumScape continues to make step-by-step progress toward commercialization of its EV battery technology.
In this article, we will take a look at the 10 best shipping and container stocks to buy now. To skip our analysis of the recent market trends and activity, you can go directly to see the 5 Best Shipping and Container Stocks to Buy Now. The shipping and container companies play an important role […]
Those following along with Local Bounti Corporation ( NYSE:LOCL ) will no doubt be intrigued by the recent purchase of…
Netlist, Inc. (NLST) delivered earnings and revenue surprises of -100% and 25.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Yahoo Finance tech editor Dan Howley breaks down Meta's third-quarter earnings results, which beat on revenue.
Does the October share price for Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) reflect what it's really worth…
Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2022 investor letter. A copy of the same can be downloaded here. The fund lost 0.32% in the third quarter compared to a 0.17% gain for the MSCI ACWI (in $A). For September, the fund gained 6.68% compared to a 3.58% loss for the MSCI […]
Devon Energy's (DVN) third-quarter earnings are likely to be driven by strong production and contributions from acquired assets in the Williston Basin.
I'm sticking to these two dividend stocks, counting on regular dividend checks for years and years to come.
Shares of Annaly Capital Management (NYSE: NLY) surged higher on Thursday, jumping 6.2% shortly after the opening bell at 9:48 a.m. ET. The markets were mixed on Thursday morning as the Dow Jones Industrial Average was up more than 400 points at around 1:15 p.m. ET. Annaly Capital Management, a mortgage real estate investment trust (REIT), posted strong third-quarter earnings after the market close on Wednesday, which sent the stock price surging higher.
In this article, we discuss the 10 best crude oil stocks to buy today. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Crude Oil Stocks To Buy Today. The energy industry rebounded sharply in 2022 from the low recorded during the pandemic. According to U.S. Energy Information […]


By admin

Leave a Reply

Your email address will not be published. Required fields are marked *